Description

Melittin is a PLA2 activator, stimulates the activity of the low molecular weight PLA2, while it does not the increase activity of the high molecular weight PLA2[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–Cancer-programmed cell death–C131H229N39O31—Cancer Lett. 2022 May 28;534:215615.|FASEB J. 2020 Nov;34(11):14892-14904.|Front Microbiol. 2020 Jul 31;11:1720.|Heliyon. 2024 Jan 4.|J Appl Microbiol. 2024 Jan 4:lxae001.|J Exp Med. 2022 May 2;219(5):e20212414.|J Integr Med. 10 October 2022.|J Pharm Pharmacol. 2023 Mar 26;rgad008.|PeerJ. 2018 Jul 25;6:e5369. |Prostate. 2023 Jul 30.|Free Radic Res. 2022 Oct 4;1-26.-[1]Steiner MR, et al. Responses of purified phospholipases A2 to phospholipase A2 activating protein (PLAP) and Melittin. Biochim Biophys Acta. 1993 Feb 10;1166(1):124-30.|[2]Alonezi S, et al. Metabolomic Profiling of the Effects of Melittin on Cisplatin Resistant and Cisplatin Sensitive Ovarian Cancer Cells Using Mass Spectrometry and Biolog Microarray Technology. Metabolites. 2016 Oct 13;6(4). pii: E35.–20449-79-0–2846.46–99.78–NC(CC[C@@H](C(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)NC([C@H](CCCCN)NC([C@H]([C@@H](C)CC)NC([C@@H](NC([C@H](CO)NC([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@H](C)NC([C@H]1N(CCC1)C([C@H](CC(C)C)NC(CNC([C@H]([C@H](O)C)NC([C@H]([C@H](O)C)NC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H](C)NC(CNC([C@H]([C@@H](C)CC)NC(CN)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC2=CNC3=CC=CC=C23)=O)=O)=O)=O)=O)=O)=O)=O–Cancer; Inflammation/Immunology–H2O : ≥ 50 mg/mL–Phospholipase—-Metabolic Enzyme/Protease–Peptides